ADC Therapeutics SA logo
ADC Therapeutics SA ADCT
$ 4.13 -5.06%

Annual report 2022
added 12-21-2024

report update icon

ADC Therapeutics SA Cost of Revenue 2011-2026 | ADCT

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue ADC Therapeutics SA

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 1.39 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.39 M 1.39 M 1.39 M

Quarterly Cost of Revenue ADC Therapeutics SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - 529 K - 502 K 121 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
529 K 121 K 384 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
421 K $ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
15.3 M - -24.86 % $ 820 K usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
2.97 B $ 7.81 -2.01 % $ 6.83 B spainSpain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
3.52 M $ 225.98 -1.32 % $ 5 B danmarkDanmark
Adverum Biotechnologies Adverum Biotechnologies
ADVM
100 K - - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
BioCardia BioCardia
BCDA
4 K $ 1.26 -0.79 % $ 26.7 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
63.6 M $ 14.2 -0.7 % $ 208 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
90 K - 5.93 % $ 314 M canadaCanada
BioNTech SE BioNTech SE
BNTX
2.91 B $ 91.19 1.21 % $ 27.2 B germanyGermany
Acasti Pharma Acasti Pharma
ACST
76 K - 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
4.74 M - - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
602 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
20.6 M $ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
161 M $ 6.67 1.6 % $ 1.07 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
238 M - - $ 867 M germanyGermany